Efficacy and Safety of Stem Cell Therapy for Crohn's Disease: a Meta-analysis of Randomized Controlled Trials

Overview

Journal Stem Cell Res Ther

Publisher Biomed Central

Date 2024 Feb 2

PMID 38303054

Authors

Yunfeng Qiu

Changfeng Li

Shihou Sheng

Affiliations

Soon will be listed here.

Abstract

Purpose: Small-scale clinical trials have provided evidence suggesting the effectiveness of stem-cell therapy (SCT) for patients diagnosed with Crohn's disease (CD). The objective of the research was to systematically assess the effectiveness and safety of SCT for individuals diagnosed with CD through a comprehensive review and meta-analysis.

Methods: A search was conducted in Medline (PubMed), CENTER (Cochrane Library), and Embase (Ovid) to find randomized controlled trials (RCTs) that assessed the impact of SCT on the occurrence of clinical remission (CR) and severe adverse events (SAE) among patients diagnosed with CD. The Cochrane Q test and estimation of I were used to assess heterogeneity among studies. After incorporating heterogeneity, a random-effects model was employed for data pooling.

Results: Overall, 12 RCTs involving 632 adult patients with medically refractory CD or CD-related fistula were included. In comparison with placebo or no treatment, SCT showed a greater likelihood of CR (odds ratio [OR] 2.08, 95% CI 1.39-3.12, p < 0.001) without any notable heterogeneity (I = 0%). Consistent results were observed in subgroup analyses based on study design, patient diagnosis, source and type of stem cells, and follow-up durations, with all p-values for subgroup analyses being greater than 0.05. The occurrence of SAE was similar among patients assigned to SCT and the placebo/no treatment cohorts (OR 0.70, 95% CI 0.37-1.33, p = 0.28; I = 0%).

Conclusions: For patients with medically refractory CD or CD-related fistula, SCT may be an alternatively effective and safe treatment.

Citing Articles

Management of Anal Fistula with Crohn's Disease.

Takano S, Nakamura Y, Tamaoka K, Yoshimoto T, Irei Y, Tsuji Y J Anus Rectum Colon. 2025; 9(1):10-19.

PMID: 39882221 PMC: 11772789. DOI: 10.23922/jarc.2024-067.

Intestinal stem cell niche: An upcoming area of immense importance in gastrointestinal disorders.

Mehra L, Bhowmik S, Makharia G, Das P Indian J Gastroenterol. 2024; 44(1):8-23.

PMID: 39514159 DOI: 10.1007/s12664-024-01699-8.

Efficacy and safety of stem cell therapy for fistula management: an overview of existing systematic reviews.

Tripathi T, Mohan S, Alfaifi H, Alfaifi H, Farasani A, R R Int J Surg. 2024; 110(12):7573-7584.

PMID: 39468970 PMC: 11634089. DOI: 10.1097/JS9.0000000000002125.

Safety and efficacy of stem cell therapy for Crohn's disease: an umbrella review of systematic reviews.

Thangavelu L, Mohan S, Alfaifi H, Alfaifi H, Farasani A, Menon S Int J Surg. 2024; 110(12):7495-7507.

PMID: 39352128 PMC: 11634090. DOI: 10.1097/JS9.0000000000002104.

References

English K . Mechanisms of mesenchymal stromal cell immunomodulation. Immunol Cell Biol. 2012; 91(1):19-26. DOI: 10.1038/icb.2012.56. View

Page M, McKenzie J, Bossuyt P, Boutron I, Hoffmann T, Mulrow C . The PRISMA 2020 statement: an updated guideline for reporting systematic reviews. BMJ. 2021; 372:n71. PMC: 8005924. DOI: 10.1136/bmj.n71. View

Lightner A, Reese J, Ream J, Nachand D, Jia X, Otero Pineiro A . A Phase IB/IIA Study of Allogeneic, Bone Marrow-derived, Mesenchymal Stem Cells for the Treatment of Refractory Ileal-anal Anastomosis and Peripouch Fistulas in the Setting of Crohn's Disease of the Pouch. J Crohns Colitis. 2022; 17(4):480-488. DOI: 10.1093/ecco-jcc/jjac172. View

Geldof J, Iqbal N, LeBlanc J, Anandabaskaran S, Sawyer R, Buskens C . Classifying perianal fistulising Crohn's disease: an expert consensus to guide decision-making in daily practice and clinical trials. Lancet Gastroenterol Hepatol. 2022; 7(6):576-584. DOI: 10.1016/S2468-1253(22)00007-3. View

Zhou C, Li M, Zhang Y, Ni M, Wang Y, Xu D . Autologous adipose-derived stem cells for the treatment of Crohn's fistula-in-ano: an open-label, controlled trial. Stem Cell Res Ther. 2020; 11(1):124. PMC: 7079384. DOI: 10.1186/s13287-020-01636-4. View

Wang R, Yao Q, Chen W, Gao F, Li P, Wu J . Stem cell therapy for Crohn's disease: systematic review and meta-analysis of preclinical and clinical studies. Stem Cell Res Ther. 2021; 12(1):463. PMC: 8375136. DOI: 10.1186/s13287-021-02533-0. View

Buie M, Quan J, Windsor J, Coward S, Hansen T, King J . Global Hospitalization Trends for Crohn's Disease and Ulcerative Colitis in the 21st Century: A Systematic Review With Temporal Analyses. Clin Gastroenterol Hepatol. 2022; 21(9):2211-2221. DOI: 10.1016/j.cgh.2022.06.030. View

Guyatt G, Oxman A, Akl E, Kunz R, Vist G, Brozek J . GRADE guidelines: 1. Introduction-GRADE evidence profiles and summary of findings tables. J Clin Epidemiol. 2011; 64(4):383-94. DOI: 10.1016/j.jclinepi.2010.04.026. View

Higgins J, Thompson S, Deeks J, Altman D . Measuring inconsistency in meta-analyses. BMJ. 2003; 327(7414):557-60. PMC: 192859. DOI: 10.1136/bmj.327.7414.557. View

10.

Parigi T, DAmico F, Abreu M, Dignass A, Dotan I, Magro F . Difficult-to-treat inflammatory bowel disease: results from an international consensus meeting. Lancet Gastroenterol Hepatol. 2023; 8(9):853-859. DOI: 10.1016/S2468-1253(23)00154-1. View

11.

Veroniki A, Jackson D, Viechtbauer W, Bender R, Bowden J, Knapp G . Methods to estimate the between-study variance and its uncertainty in meta-analysis. Res Synth Methods. 2015; 7(1):55-79. PMC: 4950030. DOI: 10.1002/jrsm.1164. View

12.

Ascanelli S, Zamboni P, Campioni D, Sibilla M, Chimisso L, Zollino I . Efficacy and Safety of Treatment of Complex Idiopathic Fistula-in-Ano Using Autologous Centrifuged Adipose Tissue Containing Progenitor Cells: A Randomized Controlled Trial. Dis Colon Rectum. 2021; 64(10):1276-1285. DOI: 10.1097/DCR.0000000000001924. View

13.

Molendijk I, Bonsing B, Roelofs H, Peeters K, Wasser M, Dijkstra G . Allogeneic Bone Marrow-Derived Mesenchymal Stromal Cells Promote Healing of Refractory Perianal Fistulas in Patients With Crohn's Disease. Gastroenterology. 2015; 149(4):918-27.e6. DOI: 10.1053/j.gastro.2015.06.014. View

14.

Zhang J, Lv S, Liu X, Song B, Shi L . Umbilical Cord Mesenchymal Stem Cell Treatment for Crohn's Disease: A Randomized Controlled Clinical Trial. Gut Liver. 2017; 12(1):73-78. PMC: 5753687. DOI: 10.5009/gnl17035. View

15.

Panes J, Bouma G, Ferrante M, Kucharzik T, Nachury M, de la Portilla de Juan F . INSPECT: A Retrospective Study to Evaluate Long-term Effectiveness and Safety of Darvadstrocel in Patients With Perianal Fistulizing Crohn's Disease Treated in the ADMIRE-CD Trial. Inflamm Bowel Dis. 2022; 28(11):1737-1745. PMC: 9629463. DOI: 10.1093/ibd/izab361. View

16.

Jiang W, Xu J . Immune modulation by mesenchymal stem cells. Cell Prolif. 2019; 53(1):e12712. PMC: 6985662. DOI: 10.1111/cpr.12712. View

17.

Lan N, Wu X, Shen B . Stem cell therapy: light in the tunnel for penetrating Crohn's disease. Gastroenterol Rep (Oxf). 2023; 11:goac085. PMC: 10039787. DOI: 10.1093/gastro/goac085. View

18.

Fu X, Liu G, Halim A, Ju Y, Luo Q, Song A . Mesenchymal Stem Cell Migration and Tissue Repair. Cells. 2019; 8(8). PMC: 6721499. DOI: 10.3390/cells8080784. View

19.

Lightner A, Reese J, Ream J, Nachand D, Dadgar N, Adams A . A phase IB/IIA study of ex vivo expanded allogeneic bone marrow-derived mesenchymal stem cells for the treatment of rectovaginal fistulizing Crohn's disease. Surgery. 2023; 175(2):242-249. DOI: 10.1016/j.surg.2023.07.020. View

20.

Zhang H, Yuan S, Meng H, Hou X, Li J, Xue J . Stem Cell-Based Therapies for Inflammatory Bowel Disease. Int J Mol Sci. 2022; 23(15). PMC: 9368934. DOI: 10.3390/ijms23158494. View